Despite significant progress in our understanding of the role of the adipocyte as an immumodulator, and evidence that circulating plasma and HDL cholesterol bound clusterin may be involved in the metabolic syndrome, insulin resistance, atherogenesis, and CV risk, the importance of adipocyte-derived clusterin in human cardiometabolic disease remains largely unknown. Here, CLU is linked to metabolic syndrome.